To reduce the resistance of melanoma to PD-1 inhibitors and improve the response rate, the combination of PD-1 inhibitors and other therapeutic methods is preferred to the independent use of PD-1 inhibitors [244]. This evidence concerns the gene PDCD1 and melanoma.